tiprankstipranks
The Fly

Vertex Pharmaceuticals price target raised to $400 from $390 at Piper Sandler

Vertex Pharmaceuticals price target raised to $400 from $390 at Piper Sandler

Piper Sandler raised the firm’s price target on Vertex Pharmaceuticals to $400 from $390 and keeps an Overweight rating on the shares after a solid Q3 print and FY23 CF product revenue guidance raised. Combining this with upside from other income and lower than expected tax expense, Vertex delivered a solid non-GAAP EPS beat, the firm adds. Piper continues to view Vertex as a core large cap holding.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on VRTX:

Questions or Comments about the article? Write to editor@tipranks.com